Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 3Plasma cell 2Myeloid 2

Conditions

Myelodysplastic Syndromes 33Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Hodgkin Disease 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Lymphoma, Non-Hodgkin 16Myeloproliferative Disorders 15Leukemia, Lymphocytic, Chronic, B-Cell 15Multiple Myeloma 14Graft vs Host Disease 14Leukemia 13Primary Myelofibrosis 11Lymphoma, Mantle-Cell 11Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Leukemia, Myelomonocytic, Chronic 10Leukemia, Myeloid, Accelerated Phase 10Lymphoma, B-Cell, Marginal Zone 9Lymphoma 9Leukemia, Myeloid, Chronic-Phase 9Burkitt Lymphoma 9Blast Crisis 9Waldenstrom Macroglobulinemia 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large-Cell, Immunoblastic 7Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 7Neoplasms, Plasma Cell 6Lymphoma, T-Cell, Cutaneous 6Lymphoma, Large-Cell, Anaplastic 6Leukemia, Prolymphocytic 6

Interventions

Imatinib Mesylate 9fludarabine 5Whole-Body Irradiation 5Tacrolimus 5Mycophenolic Acid 5Cyclophosphamide 5Busulfan 5ponatinib 4nilotinib 4fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 3Bone Marrow Transplantation 3venetoclax 2thymoglobulin 2asciminib 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Dasatinib 2Behavior Therapy 2Azacitidine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2zileuton 1spartalizumab 1sabatolimab 1nicotinamide-beta-riboside 1methanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid × Sirolimus × Myeloid × Clear all
NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
56 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Plasma Cell, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT00144703 2012-01-26

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation

Dana-Farber Cancer Institute

Phase 2 Completed
55 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Hodgkin Disease, Leukemia, Myeloid, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡